Acurx Pharmaceuticals, Inc. SEC filings ACXP
Acurx Pharmaceuticals, Inc. has 245 filings in SEC EDGAR's recent list, going back to Apr 3, 2018. Its latest annual report, Form ARS, was filed on Sep 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (bylaw or fiscal year change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 17, 2026 | — |
| EFFECT | Filing | May 11, 2026 | — |
| EFFECT | Filing | May 11, 2026 | — |
| CORRESP | Letter to the SEC | May 7, 2026 | — |
| CORRESP | Letter to the SEC | May 7, 2026 | — |
| UPLOAD | Letter from the SEC | May 7, 2026 | — |
| UPLOAD | Letter from the SEC | May 7, 2026 | — |
| D | Filing | Apr 29, 2026 | — |
| EFFECT | Filing | Feb 11, 2026 | — |
| CORRESP | Letter to the SEC | Feb 9, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 9, 2026 | — |
| EFFECT | Filing | Jan 6, 2026 | — |
| CORRESP | Letter to the SEC | Jan 2, 2026 | — |
| EFFECT | Filing | Jul 23, 2025 | — |
| CORRESP | Letter to the SEC | Jul 21, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 21, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 14, 2025 | — |
| D | Filing | Jun 27, 2025 | — |
| EFFECT | Filing | May 29, 2025 | — |
| CORRESP | Letter to the SEC | May 27, 2025 | — |
| UPLOAD | Letter from the SEC | May 27, 2025 | — |
| D | Filing | May 20, 2025 | — |
| EFFECT | Filing | Apr 14, 2025 | — |
| CORRESP | Letter to the SEC | Apr 10, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 10, 2025 | — |
| D | Filing | Mar 21, 2025 | — |
| EFFECT | Filing | Mar 19, 2025 | — |
| EFFECT | Filing | Feb 6, 2025 | — |
| CORRESP | Letter to the SEC | Feb 4, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 4, 2025 | — |
| D | Filing | Jan 17, 2025 | — |
| RW | Filing | Apr 17, 2024 | — |
| EFFECT | Filing | Jul 10, 2023 | — |
| CORRESP | Letter to the SEC | Jul 6, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 5, 2023 | — |
| EFFECT | Filing | Sep 22, 2022 | — |
| CORRESP | Letter to the SEC | Sep 20, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 19, 2022 | — |
| EFFECT | Filing | Jul 11, 2022 | — |
| CORRESP | Letter to the SEC | Jul 7, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 7, 2022 | — |
| EFFECT | Filing | Jun 24, 2021 | — |
| CERT | Filing | Jun 24, 2021 | — |
| 8-A12B | Filing | Jun 23, 2021 | — |
| CORRESP | Letter to the SEC | Jun 22, 2021 | — |
| CORRESP | Letter to the SEC | Jun 22, 2021 | — |
| CORRESP | Letter to the SEC | May 26, 2021 | — |
| UPLOAD | Letter from the SEC | May 21, 2021 | — |
| DRSLTR | Filing | May 10, 2021 | — |
| DRS/A | Filing | May 10, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 30, 2021 | — |
| DRS | Filing | Apr 5, 2021 | — |
| D | Filing | Jan 17, 2020 | — |
| D/A | Filing | Oct 30, 2019 | — |
| D/A | Filing | Oct 30, 2018 | — |
| D/A | Filing | May 31, 2018 | — |
| D | Filing | Apr 3, 2018 | — |
Showing 57 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACXP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Staten Island, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1736243
- Former names
- Acurx Pharmaceuticals, LLC (until Jun 23, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.